Copertina

Amplifying and ameliorating light avoidance in mice with photoreceptor targeting and calcitonin gene‐related peptide sensitization

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Eric A. Kaiser, Audrey Cavanah, Geoffrey K. Aguirre, Frances E. Jensen
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	Headache: The Journal of Head and Face Pain
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Migraine, idiopathic intracranial hypertension, and calcitonin gene‐related peptide antibodies
di: Irina Krikova, et al.
Pubblicazione: (2024)

Genetic migraine disorders and the response to calcitonin gene‐related peptide antagonist treatment
di: Andrea M. Kuczynski, et al.
Pubblicazione: (2025)

Evaluating dual calcitonin gene‐related peptide antagonists for chronic migraine prevention
di: Kara S. Graves, et al.
Pubblicazione: (2026)

Patient reported outcomes and the real‐world use of calcitonin gene–related peptide medications in migraine
di: Samuel K. Peasah, et al.
Pubblicazione: (2024)

Development and pharmacological characterization of novel multi‐ calcitonin gene‐related peptide and pituitary adenylate cyclase‐activating peptide receptor antagonists
di: Zoe Tasma, et al.
Pubblicazione: (2025)

Potential drug interaction between calcitonin gene‐related peptide antagonists and neonatal Fc receptor inhibitors
di: Alex Harlan, et al.
Pubblicazione: (2025)

Persistence, effectiveness, and tolerability of anti‐calcitonin gene–related peptide monoclonal antibodies in patients with chronic migraine
di: Anna de Dios, et al.
Pubblicazione: (2024)

Arterial hypertension: A safety risk of calcitonin gene‐related peptide ligand and receptor blocker class
di: David Croteau, et al.
Pubblicazione: (2026)

Patient satisfaction with calcitonin gene‐related peptide monoclonal antibodies in migraine: A multicenter prospective cohort study
di: Alba López‐Bravo, et al.
Pubblicazione: (2025)

Treatment of abdominal migraine in an 8‐year‐old child with calcitonin gene‐related peptide receptor antagonist: A case report
di: Yunzhu Tang, et al.
Pubblicazione: (2025)

Letter to the Editor regarding “Persistence, effectiveness, and tolerability of anti‐calcitonin gene‐related peptide monoclonal antibodies in patients with chronic migraine”
di: Joaquín Borrás‐Blasco, et al.
Pubblicazione: (2025)

Differences in circulating alpha‐calcitonin gene–related peptide levels in inflammatory bowel disease and its relation to migraine comorbidity: A cross‐sectional study
di: Marta Pascual‐Mato, et al.
Pubblicazione: (2024)

The pathogenic role of calcitonin gene‐related peptide and predictors of new‐onset migraine and long‐term outcomes after transcatheter atrial septal defect closure
di: Tzu‐Hsuan Su, et al.
Pubblicazione: (2024)

Comment on “Plasma calcitonin gene‐related peptide and nerve growth factor as headache and pain biomarkers in recently deployed soldiers with and without a recent concussion”
di: Gabriel Gárate, et al.
Pubblicazione: (2024)

Nonspecific oral medications versus anti–calcitonin gene‐related peptide monoclonal antibodies for migraine: A systematic review and meta‐analysis of randomized controlled trials
di: Jennifer Robblee, et al.
Pubblicazione: (2024)

Author Response to Comment on “Plasma calcitonin gene‐related peptide and nerve growth factor as headache and pain biomarkers in recently deployed soldiers with and without a recent concussion”
di: Ann I. Scher, et al.
Pubblicazione: (2024)

Calcitonin gene‐related peptide‐targeting therapies are a first‐line option for the prevention of migraine: An American Headache Society position statement update
di: Andrew C. Charles, et al.
Pubblicazione: (2024)

Calcitonin gene‐related peptide and headache: Comparison of two commonly used assay kits highlights the perils of measuring neuropeptides with enzyme‐linked immunosorbent assays
di: Michael L. Garelja, et al.
Pubblicazione: (2025)

Response to: Calcitonin gene‐related peptide and headache: Comparison of two commonly used assay kits highlights the perils of measuring neuropeptides with enzyme‐linked immunosorbent assays
di: Alicia Alpuente, et al.
Pubblicazione: (2026)

Response to Letter to the Editor regarding “Calcitonin gene‐related peptide and headache: Comparison of two commonly used assay kits highlights the perils of measuring neuropeptides with enzyme‐linked immunosorbent assays”
di: Michael L. Garelja, et al.
Pubblicazione: (2026)

The impact of fear of attacks on pain‐related disability in cluster headache: Insights from the fear avoidance model
di: Janosch Fox, et al.
Pubblicazione: (2024)

Identifying cognitive‐affective mechanisms underlying disability in episodic migraine: Using the fear avoidance model to examine interactions
di: Janosch Fox, et al.
Pubblicazione: (2025)

Perceptions of health, cognition, and pain among middle‐aged and older adults with migraine: A population‐based cross‐sectional study examining findings from the Canadian Longitudinal Study on Aging
di: Makenna K. N. Jensen, et al.
Pubblicazione: (2025)

Cortical synchronization of spontaneous trigeminal neuropathic pain monitored with in vivo optical imaging of calcium activity in freely moving mice
di: Qianxi Liu, et al.
Pubblicazione: (2026)

Validity, reliability, and sensitivity to change of the Arabic version of the Migraine‐Specific Quality‐of‐Life Questionnaire after prophylactic treatment
di: Mona Hussein, et al.
Pubblicazione: (2024)

Waning light, waxing pain: The lunar cycle's association with migraine headache occurrence
di: Alexander Yoo, et al.
Pubblicazione: (2025)

Evaluating associations of migraine‐related vertigo
di: Nazia Karsan, et al.
Pubblicazione: (2025)

Sex influences the progression of cephalic mechanical and light hypersensitivities in a mouse model of chronic migraine
di: Marie Raquin, et al.
Pubblicazione: (2025)

Headache in individuals undergoing hormone therapy for gender transition: A cross‐sectional, observational study
di: Lucia Jimena Zavala, et al.
Pubblicazione: (2025)

Anxiety and depressive symptoms and migraine‐related outcomes in children and adolescents
di: Bilal Ahmed Rizvi, et al.
Pubblicazione: (2024)

Transcutaneous electrical nerve stimulation of the occipital nerves as treatment for chronic cluster headache
di: Ida Stisen Fogh‐Andersen, et al.
Pubblicazione: (2024)

Anxiety, depression, and headache‐related disability in a large pediatric clinic–based sample
di: Christina Murphy, et al.
Pubblicazione: (2024)

Headache‐related disability as a function of migraine aura: A daily diary study
di: Delora E. Denney, et al.
Pubblicazione: (2024)

TRPM3 activation causes CGRP release in trigeminal neurons: Implications for migraine mechanisms
di: Philip V. Reducha, et al.
Pubblicazione: (2025)

A machine learning‐driven transcriptomic study reveals the key role of Romo1 in reversing central sensitization through stellate ganglion block in migraine: An interventional study based on a recurrent migraine rat model
di: Fei Yang, et al.
Pubblicazione: (2025)

Rising migraine incidence in adolescents despite stable prevalence in the US : A call for further investigation
di: Ali Reza Tavasoli, et al.
Pubblicazione: (2024)

Assessing blood pressure changes and hypertension‐related outcomes in patients with migraine treated with erenumab: A systematic review and meta‐analysis
di: Luana Miyahira Makita, et al.
Pubblicazione: (2025)

Impact of Ramadan fasting on vision and headache‐related quality of life in women with idiopathic intracranial hypertension: A prospective observational study
di: Mona Hussein, et al.
Pubblicazione: (2024)

A history of abuse is associated with more severe migraine‐ and pain‐related disability: Results from the American Registry for Migraine Research
di: Meesha Trivedi, et al.
Pubblicazione: (2024)

Milk and plasma pharmacokinetics of single‐dose ubrogepant in healthy lactating women
di: Ramesh R. Boinpally, et al.
Pubblicazione: (2025)